After struggling with COVID, Hemant Petal is back to good health, and now he is on a mission to reduce "health inequalities".
Speaking at the SIGMA Conference 2023, he spoke about his new role as Clinical Lead, Health Inequalities and Population Health Management, SE Essex Alliance,
Essex ICB.
"So, my new role is outside pharmacy, nothing to do with pharmacy. But it is important, I feel that I share some of my insights about the work that I'm doing that
might benefit you," he said.
Elaborating on the role of integrated care boards (ICBs), he said that they are designed to enhance coordination and collaboration across different healthcare
providers and settings.
The representatives from hospitals, community services, retail and social care meet on a monthly basis to "look at where there are issues to be resolved, perhaps
what can be done to improve the healthcare services."
Boehringer Ingelheim UK & Ireland has appointed Vani Manja as its new Country Managing Director and Head of Human Pharma.
Manja has been associated with Boehringer Ingelheim for over 11 years, in successful leadership roles in Germany, the United States and most recently as General
Manager, India.
Her career started as a commissioned officer in the Indian Army Ordnance Corps which preceded leadership roles at Becton Dickinson and McKinsey.
She brings extensive experience of strategy, marketing, sales, business development, people management, and cultural transformation and is passionate about tackling
healthcare inequalities and advancing sustainable healthcare.
Commenting on her new role, Manja said: "It is with great heart that I bring the spirit of conscious leadership to my new role. I look forward to being fully present
and partnering with key stakeholders in the healthcare ecosystem in our collective quest to improve health for humans and animals in the UK and Ireland."
NHS England and NHS Improvement (NHSE&I), in association with the Royal Pharmaceutical Society (RPS) and the Association of Pharmacy Technicians UK (APTUK),
has published its first inclusive pharmacy practice (IPP) bulletin, with an overarching ambition "to make community pharmacy a more inclusive environment for all
pharmacy professionals".
The IPP programme will take practical steps to improve the awareness and understanding at all levels of different cultural beliefs and attitudes, according to the
Pharmaceutical Services Negotiating Committee (PSNC).
As a member of the IPP Improving Practice and Engagement Group, PSNC has contributed to this issue of the Bulletin, which focuses on how pharmacy professionals can
help to reduce health inequalities via the detection and prevention of cardiovascular diseases.
The IPP programme, of which the Bulletin forms a part, aims to engage with local communities to help improve their health and reduce inequalities in care -
particularly among those from ethnically diverse and disadvantaged backgrounds.
The General Pharmaceutical Council (GPhC) has published a new strategy pledging to deliver equality, improve diversity and foster inclusion in all aspects of its work.
The strategy was updated after a public consultation held between April and July. It's key themes are:
To make regulatory decisions that are demonstrably fair, lawful, and free from discrimination and bias.
To use our standards to proactively help tackle discrimination and to make sure everyone can access person-centred care, fostering equality of health outcomes.To lead by example and demonstrate best practice within our organisation, holding ourselves to the same high standards we expect of others.
GPhC chair Nigel Clarke said having a strategy is vital as the pandemic has exposed "the scope and scale of inequities in society, in healthcare outcomes and in pharmacy."
"Inequality and exclusion are bad for people's health. Therefore, this strategy is fundamental to our core purpose as a regulator and our vision for safe and effective pharmacy care at the heart of healthier communities."
In a unified effort to improve women's healthcare, four leading organisations-the Company Chemists' Association (CCA), the National Pharmacy Association (NPA),
the Royal Pharmaceutical Society (RPS), and the Faculty of Sexual and Reproductive Healthcare (FSRH)-are calling for the commissioning of a National Emergency
Hormonal Contraception (EHC) service in England.
They are proposing that this service be provided free of charge through community pharmacies to women of all ages across the country.
They emphasised that such a service would "not only transform access to care for all women, but directly tackle health inequalities and vastly improve health
outcomes."
The University of Oxford's Centre for Research Equity (CfRE) has entered into a historic partnership with the Health and Social Care Research and
Development (HSC R&D) Division in Northern Ireland to advance health equity across the region and ensure everyone benefits from healthcare advancements.
Unveiled during an event at Parliament Buildings in Stormont Estate on Wednesday, this groundbreaking partnership makes Northern Ireland the first UK region
to partner with CfRE.
Supported by the Department of Health Northern Ireland and key health and social care agencies, the partnership aims to improve health outcomes and reduce
disparities through collaborative research.
Northern Ireland's Health Minister, Mike Nesbitt, highlighted that this new partnership represents "a significant step forward in efforts to address health
inequalities" in the region.
"By bringing together leading experts and resources from across sectors, we can work towards conducting research that truly benefits all of our communities," he
said.
The National Pharmacy Association (NPA) has called the future prime minister to deliver on the commitments made by the previous health secretaries to reform
primary care through a 'pharmacy first' approach and fairly fund community pharmacies to avoid closures.
In an open letter, the NPA has urged Rishi Sunak and Liz Truss, the two leadership contenders of the Conservative Party and prime ministerial candidates, to think
radically about the role of England's 11,000 pharmacies, which are on the frontline of healthcare across the country.
NPA also highlighted how pharmacies could help clear the NHS backlog, free up millions more GP appointments, dramatically improve access to primary health care and
do more to prevent ill health and support people with long term medical conditions.
"Because of our unparalleled presence in deprived areas, we also have great potential to level up access to healthcare and address health inequalities. We set these
ideas out in How We Can Help, which is an improvement plan already welcomed by many of your colleagues."
The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and
diagnostics.
Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy.
This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated.
The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier
and better diagnostic technologies, to medical devices.
The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.
"Only around half of ICSs have a Chief Pharmacist," indicating a significant gap in leadership that hampers the pharmacy sector's ability to influence
critical healthcare decision, a report on medicine optimisation by the Public Policy Projects (PPP) highlights.
In PPP's latest report, a notable concern highlighted is the inadequate representation of pharmacy leadership within Integrated Care Systems (ICSs) despite the
role of pharmacy being "central in the delivery of system priorities, with pivotal roles in improving population health and tackling inequalities".
In recent years, the role of pharmacy within the NHS has evolved significantly with recent developments including Pharmacy First Services and legislative
amendments that allows pharmacy technicians under PGDs to administer and supply medicines.
Smoking is the most significant cause of preventable deaths in England, and the health risks associated with smoking well documented. This not only puts a heavy burden on the healthcare system but also has a substantial social impact.
Its link to health inequalities is more evident because it is more prevalent amongst the most vulnerable in our society, with low educational attainment and poor socioeconomic status.
Even as smoking rates progressively reduced, these patients remained the most difficultto reach with cessation services.
Recent years have also seen many local authorities stop providing locally commissionedNHS stop smoking service, citing funding constraints. The postpandemic financial reckoning may yet see more strain on what is left in the coffers.
The Healthy Living pharmacy ethos community pharmacy teams, proactively supporting patients to quit and advising on the best evidence-shaped approach, deliver successful outcomes.
In response to new research that revealed inequality in menopause support with 51 per cent of women from black, Asian and minority ethnic backgrounds,
Holland & Barrett, the UK's leading health and wellness retailer, has decided to continue its menopause campaign work to make "every menopause matter".
A quarter of women (26 per cent) from minority ethnic communities say they find it difficult to access menopause support relevant to their specific backgrounds.
Alongside support from Olympian and menopause campaigner, Michelle Griffith Robinson and expert, Meera Bhogal, the retailer is launching several new initiatives
to make its information and support on menopause more inclusive by offering more diverse and personalised advice and content, tailored to different needs.
Almost a third (31 per cent) believe being able to speak to a female healthcare professional of the same ethnicity as them would have made a difference to their
menopause experience. Fifteen per cent go as far as saying that communicating in their native language would have made a positive difference.
Based on these findings, Holland and Barrett is the first retailer to launch a free, multi-language menopause online consultation service. The service will
see trained H&B menopause advisors offering guidance and symptom support in multiple languages, starting with Hindi, Urdu, Gujarati and Punjabi.
The recent announcement that Royal Mail will be partnering with distance selling pharmacy (DSP) giant pharmacy2U highlights how standards of regulatory
enforcement are being ignored to accommodate the DSP model.
The brunt of these double standards hinges around the levelling down of temperature enforcement standards by the Medicines and Healthcare products Regulatory
Agency (MHRA) which demands mapping must be audited from the point of dispensing to the patient.
The MHRA has a well recognised duty to ensure medicines reach patients in a safe condition. The current anomaly appears to turn a blind eye to this step in the
supply chain at the point the wholesaler releases goods to the pharmacy hub.
Equally the training on delivering medicines safely and effectively direct to patients should apply fully to all hubs including DSPs. Why is it that DSPs are being
treated differently to bricks and mortar pharmacies? It's essentially the same patients receiving the same medicines from the same wholesalers.
A further regulatory disparity exists around how parcels must be "tracked and signed for" to be reasonably certain medicines are delivered into the hand of the
intended recipient, as per existing regulations.
Clearly an untracked, unsigned package cannot be guaranteed to finish in the hands of the intended recipient.
There is a very real possibility that such omission could lead to community pharmacy closures which will, in turn, lead to unemployment and a reduction in the
care services. At a time when integrated care systems have just gone live, the removal of vital support services leading to further inequalities is the wrong
message for both providers and patients alike.
The Association of the British Pharmaceutical Industry (ABPI) has appointed Susan Rienow, country president of Pfizer, as its vice president.
"As vice president, she will support the president, Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK, in delivering his priorities.
These are improving access to medicines, delivering economic growth and helping to find solutions to big societal challenges such as climate change, AMR, and
inequalities," said ABPI in a statement.
At Pfizer, Susan leads the organisation to bring the power of innovation, data and technology together to transform healthcare and improve outcomes for patients.
She previously led Pfizer UK's vaccines business unit during the Covid-19 pandemic.
The National Pharmacy Association (NPA) highlighted the role played by community pharmacies during pandemic to provide urgent care and vital support to people
with long-term medical conditions at its opening remark in the Covid-19 public inquiry held on Tuesday (28 February).
NPA is the core participant in the Covid-19 public inquiry. lawyer Brian Stanton made an opening statement on the NPA's behalf which focused on three areas- health
inequalities and the needs of vulnerable patients; the impact of medicine shortages and medicine price increases and the challenge that community pharmacy faced in
responding to the pandemic and maintaining patient services following long-term under investment.
Stanton said: "The UK's community pharmacies were on the frontline of efforts to limit the impact of coronavirus and to keep people well, and as well as handling a
massive increase in demand for healthcare advice and medicines, they also continued to provide urgent care and vital support to people with long-term medical
conditions.
"However, there are now very many at risk of closure during to underfunding and when the Inquiry comes to consider its recommendations the NPA would encourage
you [the presiding judge] to think about how resilience can be built into future plans."
The statement included a compelling account of the commitment typical of so many pharmacies during the pandemic - from husband and wife Pete and Sukhi Johal, both
NPA members and pharmacists, who co-own Calow Pharmacy in Chesterfield.
The Royal Pharmaceutical Society (RPS) has welcomed the appointment of Michael Matheson MSP as Cabinet Secretary for NHS Recovery, Health and Social Care in
Scotland.
Commenting on the announcement Laura Wilson, Director of RPS Scotland, said: "I would like to congratulate Michael Matheson on being appointed to this position.
NHS recovery is vitally important, and pharmacy has a huge amount to offer this agenda.
"Our current priorities include enabling pharmacists to take leadership of prescribing in all care settings, tackling health inequalities and advocating for change,
implementing shared patient records between healthcare professionals to provide high-quality, person centred and safe patient care, improving pharmacists' wellbeing
and tackling the climate emergency by encouraging sustainable and green prescribing across Scotland.
Professor Mahendra Patel OBE, CEO of the Oxford University Centre for Research Equity (CfRE), has been appointed as an independent expert member of the UK
Pharmacy Professional Leadership Advisory Board.
The newly established Board comprises nine independent expert members (IEMs) with outstanding leadership capabilities, who were appointed through open recruitment,
ensuring a "broad, balanced, and diverse" representation.
Sir Hugh Taylor KCB, the Independent Chair of the Board, and the UK Chief Pharmaceutical Officers (CPhOs) - Andrew Evans (Wales), Cathy Harrison (Northern Ireland),
Alison Strath (Scotland), and David Webb (England) - announced the appointment of IEMs in an open letter to the UK pharmacy professions.
"Bringing a wealth of experience and expertise, they will play a pivotal role in the Board's work to deliver an exciting vision through supporting a new and dynamic
phase of collaboration," the CPhOs said.
As the CEO of CfRE, Professor Patel spearheads efforts aimed at addressing inequalities in healthcare.
The National Pharmacy Association (NPA) views the COVID vaccination programme as broadly successful, largely due to the efforts of healthcare workers and
volunteers.
However, it cited some areas that could be improved, notably the early involvement of community pharmacies in planning, operational challenges, and recognising
the role of community pharmacy in addressing vaccine hesitancy and inequalities.
Submitting its evidence to the Covid-19 Inquiry, the NPA highlighted that the community pharmacy should have been consulted and involved earlier in the planning
process, considering their two years of experience and expertise in administering annual influenza vaccination programs and the reach and resources of the 14,000
community pharmacies across the UK.
"Instead, community pharmacy was initially given a gap in service role, which failed to fully utilize their experience, expertise and resource," Lawyer Brian
Stanton told the Inquiry on behalf of the NPA during the Module 4 Preliminary Hearing on 22 May.
Released on Monday morning, the election manifesto shared by the Liberal Democrats pledges to "strengthen patients' rights" by tackling public health
inequalities and providing early access to community services.
The Liberal Democrats Party's manifesto promises to address the issues at both the "front and back doors" of the National Health Service (NHS), which the party
claims has been plunged into crisis by the Conservatives.
Pledging to invest in public health and early access to community services, the party aims to "work towards a fairer and more sustainable long-term funding model
for pharmacies and build on the Pharmacy First approach to give patients more accessible routine services and ease the pressure on GPs."
The pledge also includes making prescriptions for people with chronic mental health conditions free on the NHS, as part of a wider commitment to review the entire
schedule of exemptions for prescription charges.
The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) has published a report that demonstrated the importance of the
collaboration between industry and the NHS to improve patient outcomes across the UK.
Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments
in these areas continues to be below the average of similar countries in Europe.
The report, 'Transforming Lives, Improving Health Outcomes', has highlighted four initiatives where effective partnerships between the NHS, patient organisations
and industry have helped to tackle unwarranted variation in the uptake of innovative medicines.
Transforming Lives, Improving Health Outcomes also called for a systemwide secondary prevention strategy covering all parts of the health system creating a barrier
to wider and consistent uptake of innovative medicine. It also noted that newly created Integrated Care Systems have the potential to improve preventative treatment.
The report data also showed a 51% variation of uptake of three types of medicines related to diabetes between NHS Trusts in England.
Pharmacists from BAME backgrounds still face higher levels of discrimination, harassment, bullying, and career obstacles compared to their white
counterparts, the Pharmacy Workforce Race Equality Standard (PWRES) report has revealed. Published by NHSE England, this report underscores the persistent
presence of inequality, emphasising the crucial need for all stakeholders in the pharmacy sector to prioritise addressing these issues.
The PWRES report indicates that pharmacy team members of Black ethnic backgrounds are less likely to perceive equal opportunities for career advancement or
promotion within their trust. Additionally, female pharmacy team members from BAME backgrounds report higher incidents of personal discrimination in the
workplace. The report also highlights an overrepresentation of pharmacy technicians from BAME backgrounds in lower-paid roles.
"It is shocking and unacceptable to see that across all indicators the BME staff experience is worse than their white counterparts," said Tase Oputu, Chair
of RPS in England.